Skip to content
Bored Studies
RecruitingPhase 1

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

Merck Sharp & Dohme LLC · NCT07199465

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Up to age 17 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
40
US sites recruiting
21
Study start
March 30, 2026
Record last updated
October 13, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the study are to:

  • Learn what happens to letermovir in the body over time
  • Learn about the safety of letermovir and if participants tolerate it

Being studied: Letermovir

Conditions: Cytomegalovirus Prophylaxis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

The main inclusion criteria include but are not limited to the following:

  • Is a recipient of a primary or secondary allograft kidney
  • Is at least 4 weeks posttransplant and not more than 52 weeks posttransplant at the time of enrollment (Day 1) and is being managed per local standard of care
  • Has stable kidney function posttransplant
  • Has undetectable CMV deoxyribonucleic acid (DNA) from a plasma or whole blood sample collected within 14 days prior to enrollment
  • Must be able to take (as assessed by the investigator) letermovir tablets or oral pellets by mouth, or via gastrostomy or nasogastric tube (oral pellets only)
  • Does not have a condition that may interfere with the absorption of oral medication (e.g., vomiting, diarrhea, or a malabsorptive condition) from the day of enrollment (Day 1) until the intensive pharmacokinetics (IPK) sampling is completed
  • Weighs ≥2.5 and \<40 kg at enrollment (Day 1)

Exclusion Criteria

The main exclusion criteria include but are not limited to the following:

  • Has CMV disease or suspected CMV disease between screening and enrollment
  • Is on dialysis or plasmapheresis at the time of enrollment
  • Has evidence of CMV viremia at any time from screening until the time of enrollment
  • Has Child-Pugh B or C hepatic insufficiency within 14 days before enrollment
  • Is a multi-organ transplant recipient (e.g., kidney-pancreas)
  • Has any uncontrolled infection on the day of enrollment
  • Requires mechanical ventilation, or is hemodynamically unstable, at the time of enrollment
  • Has received or is receiving protocol-specified prohibited medications

Recruiting US locations

  • University of Alabama at Birmingham - School of Medicine - Pediatrics ( Site 0019)

    Birmingham, AL 35233

    Site contact: Study Coordinator · 205-638-9781

  • Children's Hospital Los Angeles ( Site 0016)

    Los Angeles, CA 90027

    Site contact: Study Coordinator · 323-660-2450

  • UCLA Clinical & Translational Research Center (CTRC) ( Site 0006)

    Los Angeles, CA 90095

    Site contact: Study Coordinator · 310-825-5225

  • Lucile Packard Children's Hospital ( Site 0001)

    Palo Alto, CA 94304

    Site contact: Study Coordinator · 408-828-5120

  • University of California Davis Health ( Site 0023)

    Sacramento, CA 95817

    Site contact: Study Coordinator · 916-734-8036

  • UCSF Medical Center at Mission Bay ( Site 0017)

    San Francisco, CA 94158

    Site contact: Study Coordinator · 415-347-1885

  • Children's Hospital Colorado ( Site 0013)

    Aurora, CO 80045

    Site contact: Study Coordinator · 720-777-6263

  • University of Miami School of Medicine ( Site 0021)

    Miami, FL 33136

    Site contact: Study Coordinator · 305-243-4445

  • Children's Healthcare of Atlanta-Center for Advanced Pediatrics ( Site 0020)

    Atlanta, GA 30329

    Site contact: Study Coordinator · 404-785-5437

  • Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 0004)

    Chicago, IL 60611

    Site contact: Study Coordinator · 312-227-2061

  • University of Michigan ( Site 0014)

    Ann Arbor, MI 48109

    Site contact: Study Coordinator · 734-936-6280

  • M Health Fairview University of Minnesota Masonic Children's Hospital, West Bank ( Site 0007)

    Minneapolis, MN 55454

    Site contact: Study Coordinator · 612-365-0013

  • Mayo Clinic - Rochester ( Site 0015)

    Rochester, MN 55905

    Site contact: Study Coordinator · 507-254-1714

  • Morgan Stanley Children's Hospital ( Site 0018)

    New York, NY 10032

    Site contact: Study Coordinator · 212-305-2500

  • Montefiore Medical Center ( Site 0024)

    The Bronx, NY 10467

    Site contact: Study Coordinator · 718-741-2426

  • Levine Children's Hospital ( Site 0022)

    Charlotte, NC 28203

    Site contact: Study Coordinator · 704-446-4842

  • Duke University-Pediatrics ( Site 0008)

    Durham, NC 27710

    Site contact: Study Coordinator · 919-684-6335

  • Cincinnati Children's Hospital Medical Center ( Site 0002)

    Cincinnati, OH 45229

    Site contact: Study Coordinator · 513-636-3017

  • Children's Hospital of Philadelphia (CHOP) ( Site 0003)

    Philadelphia, PA 19104

    Site contact: Study Coordinator · 215-590-1000

  • Children's Hospital of Pittsburgh - Department of Pediatrics ( Site 0011)

    Pittsburgh, PA 15224

    Site contact: Study Coordinator · 412-864-6893

  • Texas Children's Hospital ( Site 0005)

    Houston, TX 77030

    Site contact: Study Coordinator · 832-824-4330

Study contacts (from the official record)

  • Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
All phase 1 studies in Alabama →
A Clinical Study of Letermovir (MK-8228) in Children and… (NCT07199465) | Bored Studies